MedTrace Logo

A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

NCT06435039 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-01-31

No results posted yet for this study

Summary

The primary objective of the study is to assess safety and tolerability following administration of single doses of APL-1202 (immediate release) IR tablets and APL-1501 extended release (ER) capsules in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

APL-1202

APL-1202 IR tablets.

DRUG

APL-1501

APL-1501 ER capsules.

Sponsors & Collaborators

  • Asieris Pharmaceuticals (AUS) Pty Ltd.

    collaborator INDUSTRY

  • Syneos Health

    lead OTHER

Principal Investigators

  • Dr Christopher Argent · Asieris Pharmaceuticals (AUS) Pty Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2024-07-16
Completion
2024-07-16

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435039 on ClinicalTrials.gov